Belleville F, Bertrand F, Nabet P
Pathol Biol (Paris). 1978 Sep;26(6):348-50.
145 Determinations of beta2-microglobulin (beta2m) have been realized in 111 patients with a monoclonal gammapathy. The level of beta2m is significantly higher (p = 0,0001) in the group with monoclonal gammapathy (M = 4,75 mg/l +/- 5,62) than in normal subjects (M 1,38 mg/l +/- 0,38). In a group with monoclonal gammapathy with renal failure, the level of beta2m is higher (M = 7,07 mg/l +/- 7,76) than in a group with renal failure alone (M = 3,45 mg/l +/- 1,91). The difference is significant (p = 0,005). The level of beta2m is higher in IgA monoclonal gammapathies (M = 5,61 mg/l) than in IgG (M = 4,18 mg/l) or IgM (M = 4,37 mg/l) gammapathies, but the differences of the means between the three groups are not significant. The assay of beta-2m does not allow to distinguish myeloma (M = 3,18 mg/l +/- 1,83) from benign monoclonal gammapathy (M = 3,22 mg/l +/- 1,32) and is not useful when the diagnosis is difficult.
对111例单克隆丙种球蛋白病患者进行了β2微球蛋白(β2m)测定。单克隆丙种球蛋白病组(M = 4.75mg/l±5.62)的β2m水平显著高于正常受试者(M 1.38mg/l±0.38)(p = 0.0001)。在伴有肾衰竭的单克隆丙种球蛋白病组中,β2m水平(M = 7.07mg/l±7.76)高于单纯肾衰竭组(M = 3.45mg/l±1.91)。差异具有显著性(p = 0.005)。IgA单克隆丙种球蛋白病(M = 5.61mg/l)中的β2m水平高于IgG(M = 4.18mg/l)或IgM(M = 4.37mg/l)丙种球蛋白病,但三组之间均值的差异不显著。β2m检测无法区分骨髓瘤(M = 3.18mg/l±1.83)和良性单克隆丙种球蛋白病(M = 3.22mg/l±1.32),且在诊断困难时无用处。